Short-Term Sleep Aids for RLS Flares: Not Recommended
The 2025 AASM guidelines explicitly recommend against using traditional sleep medications (benzodiazepines like clonazepam) for RLS treatment, even during acute flares. Instead, focus on treating the underlying RLS symptoms directly rather than masking the sleep disturbance with sedatives 1.
Why Sleep Aids Are Not the Answer
The AASM specifically suggests against the use of clonazepam (conditional recommendation, very low certainty of evidence) 1. Similarly, triazolam is not recommended for periodic limb movement disorder 1. These medications may help with sleep quality superficially, but they do not address the core RLS symptoms and can lead to dependency without improving the underlying condition.
The fundamental issue is that RLS causes insomnia through its sensorimotor symptoms—the urge to move and uncomfortable sensations. Sedating a patient doesn't eliminate these symptoms; it merely makes them drowsy while still experiencing restlessness.
What to Do Instead During an RLS Flare
First-Line Approach: Alpha-2-Delta Ligands
Treat the RLS directly with gabapentin, pregabalin, or gabapentin enacarbil (all strong recommendations with moderate certainty of evidence) 1. These medications:
- Reduce RLS symptoms effectively
- Improve sleep as a secondary benefit by controlling the underlying disorder
- Do not cause augmentation (unlike dopamine agonists)
- Can be started acutely and titrated quickly
Second-Line Options for Acute Flares
Iron supplementation should be evaluated immediately:
- Check ferritin and transferrin saturation
- IV ferric carboxymaltose is strongly recommended if iron parameters are low (strong recommendation, moderate certainty) 1
- Oral ferrous sulfate can be used (conditional recommendation, moderate certainty) 1
Opioids (extended-release oxycodone and others) are suggested as an option (conditional recommendation, moderate certainty) 1. These can provide rapid symptom relief during severe flares when other treatments haven't been initiated or optimized.
Dopamine Agonists: Use with Extreme Caution
The guidelines suggest against standard use of dopamine agonists (pramipexole, ropinirole, rotigotine, levodopa) due to augmentation risk 1. However, they note these may be used short-term if the patient prioritizes immediate symptom reduction over long-term augmentation risk 1.
Critical caveat: If you choose a dopamine agonist for short-term use during a flare, you must:
- Plan for transition to an alpha-2-delta ligand or other non-dopaminergic therapy
- Monitor closely for augmentation (earlier symptom onset, increased severity, anatomic spread)
- Keep duration as brief as possible
Clinical Algorithm for RLS Flare Management
- Immediate assessment: Check iron studies (ferritin, transferrin saturation)
- Start alpha-2-delta ligand (gabapentin 300-600mg at bedtime, titrate up; or pregabalin 75-150mg at bedtime)
- If iron deficient: Add IV iron therapy
- If severe and immediate relief needed: Consider short-term opioid while alpha-2-delta ligand reaches therapeutic effect
- Avoid: Benzodiazepines, traditional sleep aids, antihistamines (which can worsen RLS)
Common Pitfalls to Avoid
- Don't prescribe "sleep medication" thinking it will help—it addresses the wrong problem and may worsen outcomes
- Don't use antihistamine-containing sleep aids (diphenhydramine, doxylamine)—these can dramatically worsen RLS symptoms
- Don't start dopamine agonists without a clear exit strategy—augmentation occurs in a significant proportion of patients and creates a more refractory condition 2
- Don't ignore iron status—even "normal" ferritin may be suboptimal for RLS (target >75-100 ng/mL)
The evidence is clear: treat the RLS, not the insomnia. When RLS symptoms are controlled, sleep naturally improves 1.